# SUCCESSOR-1 (NCT05519085)

> A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05519085
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Celgene
- Conditions: Relapsed or Refractory Multiple Myeloma
- Interventions: mezigdomide; Pomalidomide; Bortezomib; Dexamethasone
- Enrollment: 810
- Primary outcome: Progression-free Survival (PFS)

## Commentary we found

- YouTube: 26
- Podcasts: 12
- X threads: 4
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=successor-1-nct05519085

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05519085", "email": "<work email>"}; the inbox owner confirms by the emailed link.